References
- Wilson WH, Grossbard ML, Pittaluga S, et al. Dose adjusted EPOCH chemotherapy for untreated large B-cell lymphoma: a pharmacodynamics approach with high efficacy. Blood 2002;99: 2685–2693.
- Kang HJ, Kim WS, Suh C, et al. Irinotecan plus cisplatin and dexamethasone (ICD) combination chemotherapy for patients with diffuse large B-cell lymphoma previously treated with rituximab plus CHOP. Cancer Chemother Pharmacol 2008;62:299–304.
- Yamamoto K, Utsunomiya A, Tobinai K, et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T cell lymphoma. J Clin Oncol 2010;28:1591–1598.
- Ishida T, Joh T, Uike N, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol 2012;30:837–842.
- Tsukasaki K, Utsunomiya A, Fukuda H, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 2007; 25:5458–5464.
- Ishida T, Ishii T, Inagaki A, et al. The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphoma. Leukemia 2006;20:2162–2168.
- Ito A, Ishida T, Yano H, et al. Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NO/Shi-scid, IL2Rγnull mouse model. Cancer Immunol Immunother 2009;58:1195–1206.